A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults
← catalyst calendarNCT07794748 · readout in 279 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Triple · Prevention
Enrollment
4,670estimated
Sites
25
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-31
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-08 | estimated | When the study began enrolling |
| Primary completion | 2027-06-07 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-07 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pneumococcal Disease
Interventions
- Biological: PG4 Multivalent Vaccine — also filed as PG4 lot 1
- Biological: PG4 Multivalent Vaccine — also filed as PG4 Lot 2
- Biological: PG4 Multivalent Vaccine — also filed as PG4 Lot 3
- Biological: 20 Valent Pneumococcal Conjugate Vaccine (20vPnC) — also filed as Prevnar 20
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants with Prespecified Local Reactions Within 7 Days After Vaccination
measured Within 7 days after Vaccination
Percentage of Participants reporting Prespecified Systemic Events Within 7 Days after Vaccination
measured Within 7 days after Vaccination
Percentage of Participants with Adverse Events (AEs)
measured From Vaccination to 1 month after Vaccination
Percentage of Participants with Serious Adverse Events (SAEs)
measured From Vaccination to 6 months after Vaccination
OPA geometric mean ratios (GMR) between each pair of PG4 vaccine lots
measured 1 month after Vaccination
Related
PFE · their whole pipeline · Pneumococcal Disease readouts · Who in Congress owns PFE? · Executive-branch trades in PFE
PFE's other studiesmost recently updated first
- A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2/3 · Recruiting
- A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fasting Conditions Phase 1 · Completed
- Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents Phase 3 · Recruiting
- A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW) Phase 3 · Not yet recruiting
- A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM) Phase 3 · Not yet recruiting
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed